semax: the Russian neuropeptide that upregulates BDNF

semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. it is derived from the ACTH(4-7) fragment of pro-opiomelanocortin (POMC) with a C-terminal Pro-Gly-Pro stabilizing tail that confers enzymatic resistance. unlike ACTH itself, it has no corticotropic activity. it upregulates BDNF and NGF in the brain and is approved in Russia for ischemic stroke, dyscirculatory encephalopathy, and optic nerve atrophy.

what is semax?

semax is a seven-amino-acid peptide designed by combining the cognitively active core of ACTH (residues 4-7: Met-Glu-His-Phe) with a Pro-Gly-Pro glyproline tail that resists aminopeptidase cleavage. it was developed in the 1980s and received Russian Ministry of Health approval in the late 1990s.

the intellectual lineage begins with David de Wied's foundational work at Utrecht in the 1960s through 1980s, which established that POMC-derived neuropeptides have behavioral and cognitive effects entirely separate from their endocrine functions [1]. building on that platform, Ashmarin and Myasoedov at the Institute of Molecular Genetics in Moscow designed Semax by truncating the active ACTH(4-10) heptapeptide to its cognitively essential core (ACTH(4-7), four residues) and appending the Pro-Gly-Pro tripeptide, which forms a glyproline structure that resists the aminopeptidases that would otherwise destroy the peptide within seconds of systemic exposure. the result is a seven-residue sequence with the molecular formula C37H51N9O10S and a molecular weight of approximately 814 Da.

because Semax lacks the C-terminal arginine-tryptophan sequence required for binding MC2R (the ACTH receptor in the adrenal cortex), it does not stimulate cortisol release. this gives it a clean separation from HPA axis activation. it is manufactured in Russia by MNPK Peptogen and is dispensed as a prescription nasal solution at 0.1%, 0.5%, and 1% concentrations. outside Russia and Ukraine, it is available only through gray-market channels and is not regulated as an approved therapeutic in the US, EU, UK, or Australia [2].

how does it work?

semax's most consistently demonstrated molecular effect is rapid upregulation of BDNF and NGF gene expression and protein levels in the hippocampus and frontal cortex. it also modulates dopaminergic and serotonergic neurotransmission. its primary receptor target remains unidentified, which is an honest gap in the mechanism story.

the neurotrophin signal is the most robustly replicated finding in the Semax literature. Shadrina, Dolotov, and Grivennikov first demonstrated rapid induction of BDNF and NGF mRNA in rat glial cell cultures [3]. subsequent in-vivo studies confirmed regional BDNF protein increases in the rat basal forebrain and hippocampus, along with upregulation of the TrkB receptor through which BDNF signals [4]. whole-brain transcriptomic analysis by Medvedeva and colleagues extended this to broader gene-expression changes affecting immune and vascular pathways during focal ischemia [5].

on the neurotransmitter side, Eremin and colleagues demonstrated that Semax activates dopaminergic and serotonergic systems in rodents and potentiates amphetamine-induced dopamine release in the striatum. these effects are consistent with the behavioral attention-and-memory profile observed in animal models but have not been characterized in controlled human trials.

the receptor target question remains open. unlike melanotan peptides with defined melanocortin receptor affinities, Semax has no clearly identified primary receptor. proposed mechanisms include low-affinity melanocortin receptor interactions and, more recently, mu-opioid receptor involvement: a 2025 study from a non-Russian group found that Semax promoted deubiquitination of the mu-opioid receptor Oprm1 in a spinal cord injury model, identifying a mechanism distinct from the neurotrophin story [6].

what does the evidence show?

the strongest human clinical signal is in ischemic stroke and chronic cerebrovascular insufficiency, where Russian trials from Gusev, Skvortsova, and colleagues between 1997 and 2018 reported neurological benefit. these trials are small, open-label or quasi-randomized, and do not meet Western multicenter RCT standards. no controlled human trials of semax in healthy adults for cognitive enhancement have been published.

the Russian clinical program for ischemic stroke spans more than two decades. Gusev and Skvortsova first reported efficacy data in the acute phase of hemispheric ischemic stroke in 1997, followed by a mechanism-oriented follow-up in 1999 and a chronic cerebrovascular insufficiency cohort in 2005. a 2018 multistage efficacy paper updated these results and represents the most recent controlled clinical evidence [7]. the consistent direction of effect across these trials is the most credible human signal for Semax, but the absence of Western-standard trial design limits how strongly those signals can be interpreted.

the optic nerve indication, one of the three approved Russian uses, is supported by small ophthalmology trials in optic nerve disease and glaucomatous optic neuropathy. in both cases the evidence base is narrow, single-center, and not independently replicated in Western literature.

the "nootropic for healthy adults" claim that drives most gray-market interest rests almost entirely on rodent behavioral assays and extrapolation from patient-population trials. no double-blind placebo-controlled trial in healthy human adults has been conducted on semax for attention, memory, or cognitive performance. that gap is not a technicality; it is the core evidentiary limitation that any honest account of semax must state. preclinical data supporting BDNF upregulation and dopaminergic modulation is mechanistically interesting but not a substitute for human trials.

regulatory status

semax is approved in Russia and Ukraine as a prescription medication for ischemic stroke, dyscirculatory encephalopathy, and optic nerve atrophy. it is not approved by the FDA, EMA, MHRA, or TGA. in Western markets it is sold as a gray-market research chemical, a category that carries no quality, purity, or safety oversight.

the Russian approval reflects a historically different threshold applied by Roszdravnadzor compared with the FDA and EMA, which require large multicenter blinded trials with pre-specified endpoints. that difference in regulatory standards does not by itself imply Semax is unsafe or ineffective, but it does mean the evidence package used to gain Russian approval would not currently satisfy FDA or EMA requirements. seized pharmaceutical preparations containing Semax have been documented in Western markets in the context of cognitive-enhancement "research peptides," confirming its presence in gray-market supply chains [2].

where it fits in peptide science

semax belongs to a family of POMC-derived neuropeptides alongside selank (an analog of tuftsin with anxiolytic properties) and the melanocortin family. its unique feature is the BDNF/NGF upregulation profile and the approved stroke indication in Russia. compared with FDA-approved peptides like tesamorelin or semaglutide, it occupies a different tier: Russian prescription approval, preclinical robustness, but no Western regulatory validation.

its closest relative in the Peptides Academy catalog is selank, another Russian-developed neuropeptide with overlapping institutional origins at IMG RAS but a distinct mechanism focused on anxiety and immune modulation. the broader POMC family connects semax conceptually to the melanocortin peptides (melanotan-1, melanotan-2), though those peptides have defined MC1R-MC5R receptor profiles and a different evidence architecture. for context on what FDA approval actually requires, see our overview of tesamorelin, the only GHRH analog with full FDA approval. for how neuropeptides relate to the broader landscape of brain signaling, the free module peptides and your body provides the foundational biology.